<code id='192B5E9606'></code><style id='192B5E9606'></style>
    • <acronym id='192B5E9606'></acronym>
      <center id='192B5E9606'><center id='192B5E9606'><tfoot id='192B5E9606'></tfoot></center><abbr id='192B5E9606'><dir id='192B5E9606'><tfoot id='192B5E9606'></tfoot><noframes id='192B5E9606'>

    • <optgroup id='192B5E9606'><strike id='192B5E9606'><sup id='192B5E9606'></sup></strike><code id='192B5E9606'></code></optgroup>
        1. <b id='192B5E9606'><label id='192B5E9606'><select id='192B5E9606'><dt id='192B5E9606'><span id='192B5E9606'></span></dt></select></label></b><u id='192B5E9606'></u>
          <i id='192B5E9606'><strike id='192B5E9606'><tt id='192B5E9606'><pre id='192B5E9606'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:3
          Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT
          The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

          About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients. 

          A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons. 

          advertisement

          NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests  later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Biotech reporter’s notebook: A sunnier mood at JPM 2024
          Biotech reporter’s notebook: A sunnier mood at JPM 2024

          AlexHogan/STATSANFRANCISCO—Itseemedliketherewasapointduringlastyear’sJ.P.MorganHealthcareConferencew

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          How the messy conversation about Dolly changed bioethics

          SophieGogginsoftheNationalMuseumsScotlandinEdinburghviewsDollytheSheepduringtheopeningofamajornewdev